Annual EBIT
-$222.61 M
-$54.73 M-32.60%
31 December 2023
Summary:
Crinetics Pharmaceuticals annual earnings before interest & taxes is currently -$222.61 million, with the most recent change of -$54.73 million (-32.60%) on 31 December 2023. During the last 3 years, it has fallen by -$147.66 million (-197.00%). CRNX annual EBIT is now -3605.19% below its all-time high of -$5.92 million.CRNX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$87.80 M
-$5.01 M-6.06%
30 September 2024
Summary:
Crinetics Pharmaceuticals quarterly earnings before interest & taxes is currently -$87.80 million, with the most recent change of -$5.01 million (-6.06%) on 30 September 2024. Over the past year, it has dropped by -$28.82 million (-48.87%). CRNX quarterly EBIT is now -5237.20% below its all-time high of -$1.65 million, reached on 30 June 2017.CRNX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$306.77 M
-$28.82 M-10.37%
30 September 2024
Summary:
Crinetics Pharmaceuticals TTM earnings before interest & taxes is currently -$306.77 million, with the most recent change of -$28.82 million (-10.37%) on 30 September 2024. Over the past year, it has dropped by -$99.26 million (-47.84%). CRNX TTM EBIT is now -11680.61% below its all-time high of -$2.60 million, reached on 31 March 2017.CRNX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX EBIT Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -32.6% | -48.9% | -47.8% |
3 y3 years | -197.0% | -215.7% | -211.1% |
5 y5 years | -675.4% | -476.5% | -538.5% |
CRNX EBIT High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | -197.0% | at low | -215.7% | at low | -211.1% | at low |
5 y | 5 years | -675.4% | at low | -477.1% | at low | -538.5% | at low |
alltime | all time | -3605.2% | at low | -5237.2% | at low | <-9999.0% | at low |
Crinetics Pharmaceuticals EBIT History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$87.80 M(+6.1%) | -$306.77 M(+10.4%) |
June 2024 | - | -$82.78 M(+12.6%) | -$277.95 M(+12.0%) |
Mar 2024 | - | -$73.53 M(+17.3%) | -$248.16 M(+11.5%) |
Dec 2023 | -$222.61 M(+32.6%) | -$62.66 M(+6.2%) | -$222.61 M(+7.3%) |
Sept 2023 | - | -$58.98 M(+11.3%) | -$207.51 M(+8.1%) |
June 2023 | - | -$52.99 M(+10.5%) | -$191.98 M(+5.5%) |
Mar 2023 | - | -$47.98 M(+0.9%) | -$182.03 M(+8.4%) |
Dec 2022 | -$167.88 M(+55.9%) | -$47.56 M(+9.4%) | -$167.88 M(+11.0%) |
Sept 2022 | - | -$43.45 M(+1.0%) | -$151.21 M(+11.5%) |
June 2022 | - | -$43.05 M(+27.3%) | -$135.57 M(+14.3%) |
Mar 2022 | - | -$33.83 M(+9.5%) | -$118.61 M(+10.1%) |
Dec 2021 | -$107.70 M(+43.7%) | -$30.89 M(+11.1%) | -$107.70 M(+9.2%) |
Sept 2021 | - | -$27.81 M(+6.6%) | -$98.61 M(+10.5%) |
June 2021 | - | -$26.09 M(+13.8%) | -$89.25 M(+11.4%) |
Mar 2021 | - | -$22.92 M(+5.2%) | -$80.09 M(+6.9%) |
Dec 2020 | -$74.95 M | -$21.79 M(+18.1%) | -$74.95 M(+9.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2020 | - | -$18.45 M(+9.0%) | -$68.38 M(+4.9%) |
June 2020 | - | -$16.93 M(-4.8%) | -$65.15 M(+5.8%) |
Mar 2020 | - | -$17.78 M(+16.9%) | -$61.57 M(+14.4%) |
Dec 2019 | -$53.83 M(+87.5%) | -$15.21 M(-0.1%) | -$53.83 M(+12.0%) |
Sept 2019 | - | -$15.23 M(+14.1%) | -$48.05 M(+17.5%) |
June 2019 | - | -$13.35 M(+32.9%) | -$40.89 M(+23.1%) |
Mar 2019 | - | -$10.04 M(+6.5%) | -$33.23 M(+15.7%) |
Dec 2018 | -$28.71 M(+214.6%) | -$9.43 M(+16.9%) | -$28.71 M(+31.8%) |
Sept 2018 | - | -$8.07 M(+42.0%) | -$21.78 M(+35.4%) |
June 2018 | - | -$5.68 M(+2.8%) | -$16.09 M(+33.5%) |
Mar 2018 | - | -$5.53 M(+121.2%) | -$12.05 M(+32.0%) |
Dec 2017 | -$9.13 M(+51.9%) | -$2.50 M(+5.0%) | -$9.13 M(+37.7%) |
Sept 2017 | - | -$2.38 M(+44.7%) | -$6.63 M(+56.0%) |
June 2017 | - | -$1.65 M(-36.8%) | -$4.25 M(+63.2%) |
Mar 2017 | - | -$2.60 M | -$2.60 M |
Dec 2016 | -$6.01 M | - | - |
FAQ
- What is Crinetics Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals annual EBIT year-on-year change?
- What is Crinetics Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly EBIT year-on-year change?
- What is Crinetics Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals TTM EBIT year-on-year change?
What is Crinetics Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of CRNX is -$222.61 M
What is the all time high annual EBIT for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high annual earnings before interest & taxes is -$5.92 M
What is Crinetics Pharmaceuticals annual EBIT year-on-year change?
Over the past year, CRNX annual earnings before interest & taxes has changed by -$54.73 M (-32.60%)
What is Crinetics Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of CRNX is -$87.80 M
What is the all time high quarterly EBIT for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high quarterly earnings before interest & taxes is -$1.65 M
What is Crinetics Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, CRNX quarterly earnings before interest & taxes has changed by -$28.82 M (-48.87%)
What is Crinetics Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of CRNX is -$306.77 M
What is the all time high TTM EBIT for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high TTM earnings before interest & taxes is -$2.60 M
What is Crinetics Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, CRNX TTM earnings before interest & taxes has changed by -$99.26 M (-47.84%)